1887

Abstract

There are five different core types of lipopolysaccharide (LPS), and enterohaemorrhagic tend to have the R3 core type. It has been hypothesized that increased carriage of bacteria with a specific core type will induce higher levels of antibodies and protect against disease caused by bacteria carrying that specific LPS core. Approximately 320 isolates of , half from healthy human faeces and half from healthy bovine faeces have been core typed both by core-specific monoclonal antibodies, and by PCR for genes encoding the enzymes responsible for the biosynthesis of the specific core structures. Results showed that possessing R1 core LPS were most frequently detected in both human and cattle populations (63 and 49 %, respectively). Compared to the human isolates a significantly higher level of bacteria with R3 core LPS was detected among the bovine commensal (11 % compared to 4 %; < 0.05). Antibody levels to each of the specific core types were measured in serum samples from healthy humans ( = 91) and healthy cattle ( = 39). In each population the highest level of antibody detected was reactive to the R4 core. In cattle the level of anti-R3 core antibody was significantly higher than the level of anti-R1, -R2 and -K12 antibodies ( < 0.01). In summary there was a greater proportion of with R3 core type in cattle, together with a corresponding higher anti-R3 antibody level. This suggests that cattle may have greater immunity to strains with an LPS of R3 core type.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.45674-0
2004-10-01
2024-04-26
Loading full text...

Full text loading...

/deliver/fulltext/jmm/53/10/JM531003.html?itemId=/content/journal/jmm/10.1099/jmm.0.45674-0&mimeType=html&fmt=ahah

References

  1. Amor K., Heinrichs D. E., Frirdich E., Ziebell K., Johnson R. P., Whitfield C. 2000; Distribution of core oligosaccharide types in lipopolysaccharides from Escherichia coli . Infect Immun 68:1116–1124 [CrossRef]
    [Google Scholar]
  2. Appelmelk B. J., An Y. Q., Hekker T. A., Thijs L. G., MacLaren D. M., de Graaf J. 1994; Frequencies of lipopolysaccharide core types in Escherichia coli strains from bacteraemic patients. Microbiology 140:1119–1124 [CrossRef]
    [Google Scholar]
  3. Barclay G. R. 1995; Endogenous endotoxin-core antibody (EndoCAb) as a marker of endotoxin exposure and a prognostic indicator: a review. Prog Clin Biol Res 392:263–272
    [Google Scholar]
  4. Bennett-Guerrero E., Ayuso L., Hamilton-Davies C. & 7 other authors; 1997; Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery. JAMA 277:646–650 [CrossRef]
    [Google Scholar]
  5. Currie C. G., Poxton I. R. 1999; The lipopolysaccharide core type of Escherichia coli O157 : H7 and other non-O157 verotoxin-producing E.coli . FEMS Immunol Med Microbiol 24:57–62 [CrossRef]
    [Google Scholar]
  6. Currie C. G., McCallum K., Poxton I. R. 2001; Mucosal and systemic antibody responses to the lipopolysaccharide of Escherichia coli O157 in health and disease. J Med Microbiol 50:345–354
    [Google Scholar]
  7. Devine D. A., Roberts A. P. 1994; K1, K5 and O antigens of Escherichia coli in relation to serum killing via the classical and alternative complement pathways. J Med Microbiol 41:139–144 [CrossRef]
    [Google Scholar]
  8. di Padova F. E., Brade H., Barclay G. R. & 8 other authors; 1993; A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides. Infect Immun 61:3863–3872
    [Google Scholar]
  9. Erridge C., Bennett-Guerrero E., Poxton I. R. 2002; Structure and function of lipopolysaccharides. Microbes Infect 4:837–851 [CrossRef]
    [Google Scholar]
  10. Galanos C., Luderitz O., Westphal O. 1969; A new method for the extraction of R lipopolysaccharides. Eur J Biochem 9:245–249 [CrossRef]
    [Google Scholar]
  11. Galanos C., Luderitz O., Rietschel E. T. & 7 other authors; 1985; Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur J Biochem 148:1–5 [CrossRef]
    [Google Scholar]
  12. Gibb A. P., Barclay G. R., Poxton I. R., di Padova F. 1992; Frequencies of lipopolysaccharide core types among clinical isolates of Escherichia coli defined with monoclonal antibodies. J Infect Dis 166:1051–1057 [CrossRef]
    [Google Scholar]
  13. Hancock I. C., Poxton I. R. 1988 Bacterial Cell Surface Techniques Chichester, UK: Wiley;
    [Google Scholar]
  14. Hoque S. S., Ghosh S., Poxton I. R. 2000; Differences in intestinal humoral immunity between healthy volunteers from UK and Bangladesh. Eur J Gastroenterol Hepatol 12:1185–1193 [CrossRef]
    [Google Scholar]
  15. Ørskov F., Ørskov I. 1975; Escherichia coli O : H serotypes isolated from human blood.Prevalence of the K1 antigen with technical details of O and H antigenic determination. Acta Pathol Microbiol Scand Suppl 83:595–600
    [Google Scholar]
  16. Porat R., Mosseri R., Kaplan E., Johns M. A., Shibolet S. 1992; Distribution of polysaccharide side chains of lipopolysaccharide determine resistance of Escherichia coli to the bactericidal activity of serum. J Infect Dis 165:953–956 [CrossRef]
    [Google Scholar]
  17. Scott B. B., Barclay G. R. 1987; Endotoxin-polymyxin complexes in an improved enzyme-linked absorbent assay for IgG antibodies in blood donor sera to Gram-negative endotoxin core glycolipids. Vox Sang 52:272–280 [CrossRef]
    [Google Scholar]
  18. Strutz F., Heller G., Krasemann K., Krone B., Muller G. A. 1999; Relationship of antibodies to endotoxin core to mortality in medical patients with sepsis syndrome. Intensive Care Med 25:435–444 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.45674-0
Loading
/content/journal/jmm/10.1099/jmm.0.45674-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error